FDA Grants Breakthrough Therapy Designation to JNJ-6372 for NSCLC

Janssen Pharmaceutical Companies recently announced the FDA granted breakthrough therapy designation to JNJ-61186372, an EGFR-MET bispecific antibody, for the treatment of metastatic non-small cell lung cancer with EGFR exon 20 mutations.

AYAs with Certain Cancer Types Saw Improvements in 5-Year Mortality Rates

A study showed that adolescents and young adults with certain types of cancers saw significant improvements in their 5-year mortality rates, while other cancer types saw little to no significant improvement among the same demographic group.

Adults with NSCLC and Impaired Performance Status Face Shorter Survival after ICI Treatment

Adults with advanced non-small cell lung cancer and impaired performance status experience significantly shorter survival after treatment with immune checkpoint inhibitors (ICIs) and receive ICIs more often than those with better performance status.